Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss.
| Autor: | Maheux P; Clinical Research Institute of Montreal, Department of Medicine, Faculty of Medicine, University of Montreal, Canada., Ducros F, Bourque J, Garon J, Chiasson JL |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity [Int J Obes Relat Metab Disord] 1997 Feb; Vol. 21 (2), pp. 97-102. |
| DOI: | 10.1038/sj.ijo.0800372 |
| Abstrakt: | Objective: To study the effect of fluoxetine, a specific serotonin reuptake inhibitor, on insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus (NIDDM) independently of its action on body weight. Research Design and Methods: In a randomized, double-blind, placebo-controlled trial, insulin-mediated glucose disposal was measured in 12 obese patients with NIDDM on diet alone before and after four weeks of treatment with either placebo (n = 6) or fluoxetine (n = 6) at a dose level of 60 mg once a day. Insulin-mediated glucose disposal was assessed by the 2-step euglycemic hyperinsulinemic clamp technique. Patients were instructed on a weight-maintaining diet. Results: Insulin infusion at 40 mU.m-2.min-1 resulted in insulin levels of 720 +/- 70 pmol. L-1 with a mean plasma glucose value of 6.4 +/- 0.2 mmol. L-1. Compared to placebo, fluoxetine increased glucose disposal (M) by 2.4-fold (P < 0.05), the insulin sensitivity index (M/I) by 2.7-fold (P < 0.03) and the glucose metabolic clearance rate (MCR) by 2.9-fold (P < 0.03). Insulin infusion at 400 mU.m-2. min-1 elicited insulin levels of 12947 +/- 1512 pmol. L-1 with a mean plasma glucose value of 5.6 +/- 0.4 mmol. L-1. Compared to placebo, fluoxetine increased M by 30% (P = NS), M/I by 40% (P < 0.04) and MCR by 23% (P < 0.04). Patient weight remained stable throughout the study with no change in dietary intake. Conclusion: Fluoxetine improves insulin-mediated glucose disposal in obese patients with NIDDM independently of weight loss. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|